MLYS — Mineralys Therapeutics Inc. price, chart and key statistics

Price data

Price

$20.30

YTD price return

-44.06%

YTD total return

-44.06%

Next earnings

Nov 9, 2026

Market cap

1.8B2023-03 639.8M2026-10 1.8B+180.8% over the window

Enterprise value

1.7B

Shares outstanding

88.4M2022-12 6.4M2026-06 88.4M+1277.2% over the window

52W low

$20.12

52W high

$47.65

From 52W high

-57.40%

From 52W low

+0.89%

52W range

1%

Volume

Rel volume

0.80×

30D volume

1.5M

30D $ vol

38.1M

Fundamentals

EPS (ttm)

-$4.382022-12 -$5.772026-06 -$4.38-24.1% over the window

FCF (ttm)

-142.4M2023-12 -81.2M2025-12 -142.4M+75.5% over the window

FCF/share

-$1.612023-12 -$1.642025-12 -$1.73+5.7% over the window

Book value/share

$6.232022-12 -$8.142026-06 $6.23-176.5% over the window

ROE

-63.45%2023-12 -29.8%2026-06 -63.5%+112.8% over the window

ROA

-52.34%2022-12 -26.0%2026-06 -52.3%+101.0% over the window

Debt / equity

0.00×

Current ratio

34.462022-12 13.982026-06 34.46+146.4% over the window

Growth (CAGR, ttm) · 10Y

Shares

+33.38%2025-06-30 → 2026-06-3066.3M → 88.4M (+33.4% total)+29.33%2023-06-30 → 2026-06-3040.9M → 88.4M (+116.4% total)n/an/a

Per-share growth (CAGR, ttm) · 10Y

Book value/share

+31.78%2025-06-30 → 2026-06-30$4.73 → $6.23 (+31.8% total)-3.69%2023-06-30 → 2026-06-30$6.98 → $6.23 (-10.7% total)n/an/a

Price

-52.78%2025-10-16 → 2026-10-16$42.97 → $20.30 (-52.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+28.66%2023-10-16 → 2026-10-16$9.53 → $20.30 (+113.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/an/a

Total return

-52.78%2025-10-16 → 2026-10-16$42.97 → $20.30 (-52.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+28.66%2023-10-16 → 2026-10-16$9.53 → $20.30 (+113.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/an/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

-4.6×2023-03 -21.472026-10 -5.14-76.1% over the window

Fwd P/E

-9.3×

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

3.3×2023-03 2.162026-10 3.26+50.8% over the window

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

-7.94%2023-12 -23.0%2025-12 -4.8%-79.3% over the window

Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 88.4M ÷ 66.3M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.

-33.38%

Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-33.38%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($897M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.

-33.38%

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($1.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

0.00%2022-12 0.0%2026-06 0.0%

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($1.8B). Same caveat as the cash buyback yield.

0.00%2022-12 0.0%2026-06 0.0%

Vs own 10Y history

P/B

68th